Corrects share movement to 41%, not 412%, in first bullet
** Shares of contract research organization Medpace MEDP.O rise 41% to $440.02 in extended trading
** Co forecasts 2025 sales to be between $2.42 billion and $2.52 billion, up from prior range of $2.14 billion to $2.24 billion
** Analysts were expecting 2025 sales to be $2.19 billion — LSEG data
** Co posts Q2 sales of $603.3 million, above est of $538.8 million
** Co reports Q2 net income of $90.3 million, compared to $88.4 million a year ago
** Co also forecasts 2025 non-adjusted earnings per share in the range of $13.76 to $14.53
** Stock down 7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。